PDRN for Under-Eye Rejuvenation: Protocol and Product Selection

The under-eye and periorbital zone is simultaneously the most frequently cited aesthetic concern in consultation and the zone where practitioners most often choose the wrong product. Standard HA skin boosters — which work excellently for the cheeks, forehead, and neck — cause persistent lower eyelid puffiness in the periorbital zone because their hydrophilicity draws water into a space with extremely limited lymphatic drainage and 0.3–0.5mm of overlying skin.

PDRN (polydeoxyribonucleotide) solves this problem elegantly. Its regenerative mechanism — adenosine A2A receptor activation driving fibroblast proliferation, collagen synthesis, and VEGF-mediated angiogenesis — operates without any water-attracting hydrophilicity. PDRN improves the under-eye skin quality from the inside, producing the kind of progressive, natural-looking improvement that patients with this concern consistently describe as 'looking less tired' — without the risk of making them look puffier.

This guide covers the complete periorbital PDRN clinical framework: why the zone requires a different approach, how PDRN's mechanism is ideally suited to it, the specific injection protocol, product selection criteria, what outcomes to expect, and how to manage the common clinical questions that arise. It is part of Celmade's PDRN/Polynucleotide cluster — for the full clinical background, see the Complete Practitioners Guide to Polynucleotides and PDRN. For the broader under-eye treatment overview, see Best Skin Boosters for Under-Eye Rejuvenation.

Why the Periorbital Zone Demands a Different Approach

The clinical properties of the periorbital zone that determine product and technique requirements are well understood — but worth revisiting in the context of PDRN specifically, because they are precisely the properties that make PDRN the most appropriate primary product for this zone:

Skin Thickness: 0.3–0.5mm

The lower eyelid skin is the thinnest on the face. Any product with volume or water-attracting capacity will be visible through this skin. A 0.1ml bolus that would be invisible in the cheek creates a visible ridge under the eyelid. Any post-treatment swelling that would be minor elsewhere becomes immediately apparent in this zone.

PDRN's solution: it does not add volume and carries no hydrophilicity. A correctly placed periorbital PDRN injection stimulates biological change in the tissue without contributing any physical swelling from water attraction.

Lymphatic Drainage: Limited and Slow

The periorbital area drains via the facial lymphatic network, and lymphatic drainage in this zone is sluggish compared to other facial areas — particularly in older patients and those with subclinical inflammatory conditions. Products that attract water (HA skin boosters) overwhelm this limited drainage capacity. Retained fluid produces the persistent under-eye puffiness that makes patients regret having the area treated.

PDRN's solution: no hydrophilicity, no additional fluid load. The regenerative mechanism occurs at the cellular level without introducing water-attracting molecules into the tissue.

Absence of Subcutaneous Fat Buffer

In most facial zones, subcutaneous fat sits between the skin and deeper structures, providing a buffer that absorbs product placed at different depths and makes technique somewhat forgiving. In the lower eyelid, this fat buffer is minimal — the orbicularis oculi muscle lies directly beneath the thin skin. Injecting deeper than the superficial dermis in this zone places product directly into or below the muscle, not into a forgiving fat layer.

Why HA Skin Boosters Fail Here

The properties that make HA skin boosters excellent for the face — hydrophilicity, water-holding capacity, immediate hydration depot — become liabilities in the periorbital zone. A product that holds 1,000 times its weight in water, injected into a zone with thin skin, no fat buffer, and poor lymphatic drainage, predictably causes:

•        Persistent lower eyelid oedema — visible as puffiness or 'pillow-face' under the eye

•        Prolonged post-treatment swelling extending beyond 48–72 hours

•        Patient dissatisfaction attributing worsened appearance to the treatment

•        Potential Tyndall effect (bluish discolouration) if high-concentration HA is placed very superficially

What PDRN Specifically Addresses in the Periorbital Zone

PDRN's periorbital effects are driven by its A2AR-mediated biological programme, operating through several simultaneously active pathways:

Product Selection for Periorbital PDRN Treatment

Not all PDRN products are equally appropriate for periorbital use. The following product properties should be confirmed before treating this zone:

Concentration

Lower PDRN concentrations reduce the total biological stimulus load per injection, which is appropriate for the periorbital zone where the tissue environment is confined and the injection volumes are small. Products formulated at 2–5 mg/ml PDRN are typically appropriate for periorbital use. Higher-concentration products designed for full-face or scalp use may produce more post-injection reactivity than is desirable in this zone.

Molecular Weight Range

PDRN in the 80–500 kDa range is appropriate for periorbital use — sufficiently small to penetrate the dermis effectively without triggering the more pronounced inflammatory response associated with very low MW fragments. Products with specified molecular weight in the product documentation are preferable to those with no MW information provided.

Additional Ingredients

Some PDRN formulations include additional excipients — mannitol, hyaluronic acid additives, amino acids. For periorbital use, check whether any additional ingredient introduces hydrophilicity or swelling tendency. A pure PDRN preparation or a PDRN formulation with only physiologically neutral excipients is the safest choice for this zone.

Absence of Crosslinked HA

Any product that contains crosslinked HA — even in small quantities — is not appropriate for periorbital use as a skin quality treatment. The G-prime and water-holding capacity of crosslinked HA in this zone causes the same problems as standard filler.

Periorbital PDRN Injection Protocol

The periorbital PDRN protocol is the most technically demanding application in biorevitalisation practice. Precision of depth, volume, and zone boundaries is more critical here than in any other zone. The following protocol applies to a trained aesthetic practitioner familiar with periorbital anatomy:

Pre-Treatment Assessment and Consent

1.     Photograph: Standardised photographs (frontal, three-quarter, lateral) taken at the start of every session before any treatment. Essential for objective outcome comparison at review.

2.     Assess periorbital anatomy: Distinguish skin quality concern (appropriate for PDRN) from structural fat hernation (not appropriate for any injectable biorevitalisation). If significant fat hernation is present, PDRN is not the correct treatment — refer or manage expectations accordingly.

3.     Confirm indication: Crepey skin texture, dark circles with skin quality component, skin thinning, fine periorbital surface lines. Document the specific concern being treated.

4.     Confirm product suitability: Verify that the PDRN product selected is appropriate for periorbital use — confirm concentration, MW range, and absence of hydrophilic additives.

5.     Consent for periorbital-specific risks: Bruising (high risk in this zone), transient post-injection swelling, incomplete or slow response (regenerative mechanism is slower than HA hydration). Advise 10–14 days before any important event or appearance.

Anaesthesia

The periorbital zone is highly sensitive. Adequate topical anaesthesia is essential for patient comfort and for enabling the practitioner to work precisely without patient movement from pain:

•        EMLA cream (lidocaine 2.5% + prilocaine 2.5%) or equivalent: Apply under occlusion (clingfilm or tegaderm) for 45–60 minutes before treatment. 60 minutes is preferable for the periorbital zone — longer application time provides more reliable anaesthesia in this sensitive area.

•        Remove completely: Wipe the treatment area thoroughly with saline before injecting. Residual topical anaesthetic on the skin surface can interfere with the practitioner's skin tension assessment and may affect product distribution.

•        Ice immediately before: Apply an ice roller or wrapped ice pack to the periorbital zone for 2 minutes immediately before injecting each side. This provides additional anaesthesia through mild vasoconstriction and cold desensitisation, and simultaneously reduces bruising risk by vasoconstricting the periorbital vessels.

Step-by-Step Injection Technique

6.     Patient position: Supine with head elevated slightly (15–20 degrees) to reduce dependent periorbital oedema before treatment.

7.     Skin tension: Use the non-dominant hand to stretch the lower eyelid skin taut before each injection. The thin, mobile periorbital skin folds if not tensioned — injection into folded skin increases the risk of epidermal placement and excessive papule formation at a single point.

8.     Needle: 32G or 33G, 4mm or 6mm length. The finest available needle gauge for this zone. A 13mm needle is too long for periorbital use — the risk of inadvertent deeper placement is too high with longer needles in this confined anatomy.

9.     Angle: 15–20 degrees maximum — extremely shallow. The needle should be nearly parallel to the skin surface. This shallow angle targets the very superficial dermis and reduces the risk of inadvertent muscle or septal penetration.

10.  Insertion depth: 1–2mm below the skin surface. The needle tip should be barely detectable through the skin when correctly placed in the superficial dermis of this zone.

11.  Volume per point: 0.005–0.01ml maximum per injection point. This is less than half the volume used in standard full-face nappage. Smaller volumes reduce the risk of product accumulation creating visible swelling.

12.  Injection points: 5–10 points per side across the periorbital zone, working from medial to lateral. Stay within the defined zone boundaries: no injection inferior to the orbital rim, no injection medial to the medial canthus, no injection onto the eyelid above the lower lash line.

13.  Withdrawal and pressure: After each injection, withdraw the needle and immediately apply gentle pressure with a cotton tip for 3–5 seconds. This reduces bruising from individual vessel punctures.

14.  Post-treatment cooling: Apply ice gently to the treated zone for 3–5 minutes after completing each side. Cool — do not press firmly or massage.

Zone Boundaries — Critical Safety Limits

Complete Periorbital PDRN Treatment Protocol

Combining PDRN with Other Periorbital Treatments

Periorbital PDRN works best as part of a coordinated treatment plan addressing both the skin quality and any structural or dynamic components of the patient's concern:

Expected Outcomes: What to Tell Patients

Setting accurate expectations for periorbital PDRN treatment is critical to patient satisfaction. The regenerative mechanism produces results more slowly and more subtly than HA skin boosters — and for a zone where patients are often acutely focused on every change, this needs clear communication:

•        Week 1–2: Mild post-injection redness resolves within 24–48 hours. Some patients notice a very subtle improvement in skin texture. Most see no visible change yet. This is expected and normal — the fibroblast stimulation has begun but collagen synthesis takes weeks.

•        Week 4 (after session 2): First visible improvement in periorbital skin texture for most patients. The 'glass-smooth' quality of improvement begins. Skin feels slightly firmer and looks less crepey in photography comparison. Patients should be reviewing their before photographs at this point to appreciate the change.

•        Week 8–12 (after sessions 2–3): Meaningful improvement visible. Skin quality around the eyes looks better — less crepey, slightly brighter, less dull. Dark circles with a skin quality component are less pronounced. The improvement is not dramatic — it is natural-looking and the response patients describe as 'looking more rested'.

•        Week 12+ (post-induction assessment): Full assessment at week 12 against baseline photographs. Most patients are clearly improved in objective photography. Patient satisfaction is highest when the photographic comparison is shown — because the change is obvious in side-by-side photography even when the patient has stopped noticing it gradually in the mirror.

Managing Common Complications and Concerns

Bruising

Bruising is the most common complication and must be discussed as an expected possibility rather than an unexpected event. The periorbital skin is thin and highly vascular — even with optimal technique, some patients will bruise. Manage proactively:

•        Pre-treatment: advise avoiding alcohol and NSAIDs/aspirin 24 hours before treatment

•        At treatment: use finest available needle (32–33G), ice pre-injection, apply immediate pressure after each point

•        Post-treatment: topical arnica gel applied 3× daily to bruised area, continued for 5–7 days

•        Scheduling: advise a minimum 10–14 day gap before any important events or professional photography

Post-Treatment Swelling

Some swelling for 24–48 hours is normal. Persistent swelling beyond 72 hours that is significant warrants assessment. The most likely cause is inadvertent HA use in the zone (if any HA was introduced), or an unusual inflammatory response in a patient with pre-existing periorbital oedema tendency. Pure PDRN should not cause significant persistent oedema.

Asymmetric Response

Because each eye is treated independently and the periorbital anatomy may differ subtly between sides (one eye more hollowed, slightly different skin thickness), results may appear asymmetric before the full induction course is complete. Address this at the week-12 assessment — a 4th session on the less-improved side resolves most asymmetries. Photograph both sides at every session to monitor.

Patient Reporting No Improvement After Session 1

This is expected and must be pre-empted at consultation. PDRN works cumulatively — session 1 initiates the fibroblast response, session 2 builds on it, and the result is most apparent after session 3 and into the weeks following. A patient who reports no change after session 1 is responding normally. The risk is that they do not return for sessions 2 and 3, and therefore never experience the outcome that the treatment produces. Pre-empt this by explicitly telling patients at consultation: 'You will not see the result after one session. The treatment works over three sessions — that is how it is designed and that is what the evidence shows.'

Key Takeaways

•        PDRN is the mechanistically ideal injectable for the periorbital zone — no hydrophilicity means no oedema risk. The regenerative mechanism operates without adding any water-attracting substance to the most drainage-limited zone on the face.

•        Standard HA skin boosters should not be used in the periorbital zone — their hydrophilicity predictably causes post-treatment puffiness in a zone with thin skin, no fat buffer, and poor lymphatic drainage.

•        PDRN addresses skin quality, not structural problems — crepey texture, skin thinning, and the skin quality component of dark circles all respond. Orbital fat hernation and vascular dark circles do not respond and are not indications for injectable biorevitalisation.

•        Technique is more conservative than standard face nappage throughout — 32–33G needle, 15–20 degree angle, 0.005–0.01ml per point, 5–10 points per side, strict zone boundaries.

•        Results build over 3 sessions and are most apparent at the week-12 assessment — photograph at every session and show the before/after comparison at week 12. This moment generates more patient satisfaction and referrals than any other point in the treatment journey.

•        Korean PDRN products from Celmade are well-suited to periorbital use — MFDS-approved and CE-marked, formulated at concentrations appropriate for this zone, with full product documentation for clinical decision-making. Browse the PDRN and PN range.

For related guides: Complete Polynucleotides and PDRN Guide, Best Skin Boosters for Under-Eye Rejuvenation, Complete Skin Boosters Guide, and Combining Skin Boosters with Other Treatments.

Frequently Asked Questions

Why does PDRN not cause puffiness under the eyes like skin boosters do?

PDRN does not contain hyaluronic acid and has no hydrophilicity — it does not attract or hold water. Standard HA skin boosters are hydrophilic by design, drawing water from surrounding tissue into the injection site. In the periorbital zone, where lymphatic drainage is limited and overlying skin is 0.3–0.5mm thin, this water-holding effect produces visible post-treatment puffiness. PDRN's mechanism is biological signalling through the adenosine A2A receptor — it triggers cellular regeneration without introducing any water-attracting molecule into the tissue.

How many sessions does periorbital PDRN require?

The standard protocol is 3 induction sessions spaced 4 weeks apart, followed by maintenance every 3–4 months. The periorbital zone benefits from slightly more frequent maintenance (3–4 months rather than 6 months) because the skin here is continuously stressed by facial expression, eye movement, and UV exposure. Most patients see the first meaningful improvement after session 2, with the full induction result visible at the week-12 assessment.

Can I combine periorbital PDRN with tear trough filler in the same session?

Technically possible in experienced hands with strict tissue depth separation — tear trough filler is placed preperiosteally (very deep), PDRN is placed intradermally (very superficial). However, separate sessions with a 4-week minimum interval are generally preferred. This allows each treatment to be assessed independently, complications attributed correctly, and the skin quality to improve before structural filler is placed. For most practitioners, separate sessions is the correct approach.

Is periorbital PDRN appropriate for younger patients (25–35)?

Yes — for younger patients with genuine periorbital skin quality concerns (crepey texture, skin thinning from UV, fine surface lines), PDRN is appropriate and produces excellent results. It is also useful preventatively for patients in this age range who want to maintain the periorbital skin quality they have. The conservative technique protocol is identical regardless of patient age — the anatomy does not change based on age, only the degree of skin quality decline varies.

What if the patient's dark circles don't improve after the full course?

Dark circles are one of the most complex under-eye concerns because they have multiple causes that require different treatments. If dark circles persist after a full PDRN induction course, assess the cause more specifically: vascular dark circles (blue-purple, worse when tired) are not significantly addressed by PDRN and may need topical brightening agents, chemical peels, or vascular laser. Pigmentary dark circles require depigmentation approaches. Structural shadow from tear trough hollowing requires appropriate low G-prime filler. In each case, be honest with the patient — PDRN specifically addressed the skin quality component, which may have improved even if the overall dark circle appearance remains from a different cause.